Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open label, Multicentre, Phase I study of Ibrutinib and 3rd Party EBV specific T cells in Patients with immunosuppression related EBV-positive Brain and/or Systemic B cell lymphomas, that are relapsed/refractory or unsuitable for standard first-line treatments.

Next Previous
Trial Profile

An Open label, Multicentre, Phase I study of Ibrutinib and 3rd Party EBV specific T cells in Patients with immunosuppression related EBV-positive Brain and/or Systemic B cell lymphomas, that are relapsed/refractory or unsuitable for standard first-line treatments.

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Epstein-Barr virus vaccine (Primary) ; Ibrutinib (Primary)
  • Indications B-cell lymphoma; Lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms TREBL-1

Most Recent Events

  • 27 Mar 2020 Planned End Date changed from 1 Dec 2024 to 20 Dec 2029.
  • 16 Jul 2019 Planned End Date changed from 1 Dec 2022 to 1 Dec 2024.
  • 16 Jul 2019 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top